Acquisition of medical equipment distributor aims to strengthen European commercial operations and optimise distribution costs
While Drugs for Neglected Diseases initiative (DNDi) drives the R&D for neglected diseases, we collaborate with pharmaceutical companies at multiple stages, including sourcing promising molecules
With the convergence of AI, robotics, and neuroscience, Motorica is advancing toward more intuitive, intent-driven prosthetic systems
The partnership integrates BD’s ZebraSci, a device-agnostic testing platform, with Suttons Creek’s expertise in combination product development and systems integration
The Danish biotech company confirmed the global study will begin in the second half of 2026
Our company remains focused on advancing monoclonal antibody therapeutics for solid tumors, with a clear emphasis on combination immunotherapy strategies
Collaboration to accelerate mRNA neoantigen therapy development for colorectal and pancreatic cancers using advanced immunology and dark genome insights
With big pharma leaning on external pipelines, the company sees opportunity in de-risked, high-impact assets with clear clinical endpoints
The acquisition brings three established small-molecule drug substance facilities into Siegfried’s global network
Our company is prioritising deeper collaborations with CDMOs and biosimilar companies as part of its strategy to expand its footprint across India, Middle East, and Africa region
Subscribe To Our Newsletter & Stay Updated
